Paramesu Biotech Ltd is one of the best companies in maize-based products manufacturing, along with an 800 TPD capacity. Moreover, Paramesu has decided to launch an IPO, therefore they have filed DRHP and now it got SEBI approval for IPO worth ₹600 cr equity shares, consisting of a fresh issue of ₹520 Cr equity shares and OFS ₹80 cr equity shares with the face value ₹5 each share.
Pantomath Capital Advisor Pvt Ltd is the lead manager of the IPO proceeds and Big Share Services Pvt Ltd is assigned as the registrar of this IPO. In Paramesu IPO, QIB has 50% allocation, 35% for retailers, and 15% NII.
The Andhra Pradesh-based company may look to raise up to ₹90 crore through a pre-IPO placement. If this amount is raised, it will be deducted from the fresh issue.
IPO proceeds, Rs85 cr would be allocated to debt repayment and the rest of the money goes for general purposes.
Founded in 2011, Paramesu Biotech Limited (PBL) is a company specializing in maize-based products. The company began its commercial operations in 2015 with a capacity of 160 TPD. This company has a famous place to operate production unit, namely “Andhra Pradesh’s West Godavari District, Devarapalli.
It has established a strong foothold in both domestic and international markets.
ALMS Food Private Limited, Shree Vijay Oils, Shri Guru Oil Industries, Vikas Cattlefeed, PT Torabika Eka Semesta, Lotus Essential SDN BHD, Emami Paper Mills Limited, Tunav Food Products LLP, Singhania Foods International, Prayagh Consumer Care Private Limited, S.A. Pharmachem Private Limited and PT.
Are the major or key customers of Paramesu Biotech Ltd.
Paramesu Biotech Ltd has a national and international presence for its products due to a wide range of products, market position, focus on quality, and expanding production capabilities.
Paramesu Biotech IPO Prospectus:
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | To be Updated Soon |
Paramesu Biotech Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax |
| 2022 | ₹496.60 | ₹450.60 | ₹33.97 |
| 2023 | ₹625.34 | ₹581.32 | ₹32.52 |
| 2024 | ₹629.29 | ₹574.86 | ₹40.34 |
| September 2024 | ₹409.39 | ₹373.35 | ₹26.85 |
Paramesu Biotech IPO Valuation – FY2024
Paramesu Biotech IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Earning Per Share (EPS): | ₹1.54 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 23.30% |
| Net Asset Value (NAV): | ₹6.59 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Sanstar Limited | 4.75 | 24.82 | 30.92 | 15.37 | 1,081.68 Cr. |
| Gujarat Ambuja Exports Limited | 7.54 | 16.38 | 12.49 | 60.37 | 5,071.42 Cr. |
| Gulshan Polyols Limited | 2.85 | 71.67 | 3.01 | 94.65 | 1,390.18 Cr. |
| Sukhjit Starch and Chemicals Limited | 15.99 | 15.67 | 9.94 | 160.88 | 1,385.03 Cr. |
Objects of the Issue
- Funding the capital expenditure requirement for setting up of new plant of 1200 TPD at our Proposed Facility in Mohasa – Babai, District Narmadapuram, Madhya Pradesh.
- Repayment and/ or pre-payment, in part or full, of certain borrowings availed by our Company; and
- General Corporate Purposes.
IPO Lead Managers aka Merchant Bankers
- Pantomath Capital Advisors Private Limited
